| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
42,345,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vera Therapeutics is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Co.'s primary product candidate, atacicept, a self-administered fusion protein that blocks both blisibimod and APRIL, is being evaluated for the treatment of immunoglobulin A nephropathy in a global, randomized, double-blind, placebo-controlled clinical trial. Co. has obtained worldwide, exclusive development and commercial rights from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., for MAU868, a potentially monoclonal antibody to treat BK viremia infections.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
161,290 |
614,507 |
4,957,633 |
| Total Buy Value |
$0 |
$4,999,990 |
$11,881,994 |
$42,392,668 |
| Total People Bought |
0 |
1 |
3 |
8 |
| Total Buy Transactions |
0 |
1 |
3 |
27 |
| Total Shares Sold |
958,650 |
2,008,650 |
2,016,840 |
2,287,944 |
| Total Sell Value |
$39,017,864 |
$57,917,864 |
$58,054,276 |
$63,362,460 |
| Total People Sold |
3 |
4 |
7 |
8 |
| Total Sell Transactions |
6 |
7 |
10 |
41 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fordyce Marshall |
President and CEO |
• • – |
2022-09-09 |
4 |
AS |
$20.16 |
$259,771 |
D/D |
(12,886) |
181,150 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2022-09-09 |
4 |
OE |
$2.90 |
$37,328 |
D/D |
12,886 |
194,036 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2022-09-08 |
4 |
AS |
$20.52 |
$309,975 |
D/D |
(15,106) |
181,150 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2022-09-08 |
4 |
OE |
$2.90 |
$43,759 |
D/D |
15,106 |
196,256 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2022-09-07 |
4 |
AS |
$20.03 |
$135,904 |
D/D |
(6,785) |
181,150 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2022-09-07 |
4 |
OE |
$2.90 |
$19,655 |
D/D |
6,785 |
187,935 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-09-07 |
4 |
AS |
$18.63 |
$18,406 |
D/D |
(988) |
28,797 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2022-09-02 |
4 |
AS |
$20.26 |
$358,453 |
D/D |
(17,096) |
181,150 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2022-09-02 |
4 |
OE |
$2.90 |
$49,524 |
D/D |
17,096 |
190,900 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2022-09-01 |
4 |
AS |
$21.22 |
$362,783 |
D/D |
(17,100) |
181,150 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2022-09-01 |
4 |
OE |
$2.90 |
$49,535 |
D/D |
17,100 |
198,250 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-08-22 |
4 |
AS |
$18.42 |
$30,764 |
D/D |
(1,630) |
29,785 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-08-22 |
4 |
OE |
$11.00 |
$17,930 |
D/D |
1,630 |
30,385 |
|
- |
|
| Young Joseph R |
SVP, Finance, Chief Acct Offcr |
• – – |
2022-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
16,148 |
|
- |
|
| Lin Celia |
Chief Medical Officer |
• – – |
2022-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
12,500 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2022-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
43,750 |
181,150 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-08-19 |
4 |
AS |
$18.61 |
$132,625 |
D/D |
(6,909) |
29,785 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-08-19 |
4 |
OE |
$2.90 |
$53,500 |
D/D |
6,909 |
30,689 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
29,785 |
|
- |
|
| Grant Sean |
Chief Financial Officer |
• – – |
2022-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
33,750 |
35,268 |
|
- |
|
| Carlyle Genesis Uk Llc |
10% Owner |
– – • |
2022-08-17 |
4 |
S |
$19.88 |
$201,026 |
I/I |
(9,925) |
2,960,231 |
|
- |
|
| Carlyle Genesis Uk Llc |
10% Owner |
– – • |
2022-08-17 |
4 |
OE |
$11.00 |
$109,175 |
I/I |
9,925 |
2,970,156 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2022-08-12 |
4 |
AS |
$20.16 |
$413,799 |
D/D |
(20,528) |
137,400 |
|
- |
|
| Fordyce Marshall |
President and CEO |
• • – |
2022-08-12 |
4 |
OE |
$2.90 |
$59,466 |
D/D |
20,528 |
157,928 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-08-03 |
4 |
AS |
$16.81 |
$16,608 |
D/D |
(988) |
17,285 |
|
- |
|
134 Records found
|
|
Page 4 of 6 |
|
|
